Basilea Pharmaceutica (OTCMKTS:BPMUF – Get Free Report) will likely be releasing its resultson Tuesday, August 18th. Analysts expect the company to post earnings of $4.14 per share and revenue of $137.5660 million for the quarter.
Basilea Pharmaceutica Price Performance
OTCMKTS BPMUF opened at $65.50 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.11 and a quick ratio of 4.68. Basilea Pharmaceutica has a 52-week low of $59.29 and a 52-week high of $74.00. The firm has a 50-day moving average price of $61.43 and a 200 day moving average price of $66.91.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Featured Stories
- Five stocks we like better than Basilea Pharmaceutica
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
